Month: May 2023
Subcutaneous Rituximab Demonstrates Superior Outcomes Compared to Intravenous Administration in low–tumor burden follicular lymphoma – Phase III trial (FLIRT)
Subcutaneous Rituximab Demonstrates Superior Outcomes Compared to Intravenous Administration: Enhanced Complete Response Rates and Prolonged Progression-Free Survival – phase III trial (FLIRT) in low tumor…
Addition of Cabozantinib with immunotherapy Ipilimumab (IPI) and Nivolumab (NIVO) in previously untreated advanced clear-cell renal cell carcinoma (RCC) showed PFS benefit in intermediate risk group: COSMIC-313 trial
The COSMIC-313 trial is a phase III clinical trial that investigated the efficacy and safety of combining cabozantinib with the immunotherapy drugs ipilimumab (IPI) and…
MET Inhibitors: Promising Treatment Options for Non-Small Cell Lung Cancer
Capmatinib (Tabrecta) is a type of MET inhibitor that has shown promising results in the treatment of non-small cell lung cancer (NSCLC) that has a specific…